Education
About Us
Working with TipRanks
Follow Us
Pelthos Therapeutics (PTHS)
:PTHS
Earnings Data
Report Date
Nov 13, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.58Last Year’s EPS
-2.93Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted Pelthos' strong launch of ZELSUVMI and strategic growth plans, including a sales force expansion and acquisition of Xepi. However, the company faces challenges with high operating losses and uncertain long-term GTN levels. Overall, the positive aspects of strong revenue growth and strategic positioning outweigh the financial challenges.Company Guidance
Successful Launch of ZELSUVMI
Pelthos launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, achieving strong initial demand and $7.1 million in net product revenue in Q3 2025.
Expansion of Sales Force
Due to strong initial performance metrics, Pelthos plans to expand its sales force by adding 14 new representatives to cover more metropolitan areas.
Positive Revenue and Growth Metrics
The company reported a 41% increase in prescribed units from September to October, with a $52 million annual gross revenue run rate by the last week of October.
Strong Cash Position
Pelthos ended Q3 2025 with $14.2 million in cash and no debt, supported by a recent $18 million convertible notes financing.
Strategic Acquisition of Xepi
Pelthos acquired Xepi, an FDA-approved treatment for impetigo, to complement its existing product portfolio and leverage its commercial infrastructure.
PTHS Earnings History
Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release | Slides | Play Transcript |
|---|---|---|---|---|---|---|---|
Nov 13, 2025 | 2025 (Q3) | -2.926 | -81.13% (-2.37) | ― | |||
Aug 18, 2025 | 2025 (Q2) | -3.068 | -75.36% (-2.31) | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PTHS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $37.40 | $34.68 | -7.27% |
Aug 18, 2025 | $20.96 | $21.26 | +1.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pelthos Therapeutics (PTHS) report earnings?
Pelthos Therapeutics (PTHS) is schdueled to report earning on Nov 13, 2025, Before Open (Confirmed).
What is Pelthos Therapeutics (PTHS) earnings time?
Pelthos Therapeutics (PTHS) earnings time is at Nov 13, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTHS EPS forecast?
PTHS EPS forecast for the fiscal quarter 2025 (Q3) is -0.58.